Development and Pharmacokinetic Evaluation of Novasomes for the Trans-nasal Delivery of Fluvoxamine Using Arachidonic Acid-Carboxymethyl Chitosan Conjugate.
antidepressant activity
arachidonic acid-carboxymethyl chitosan (AA-CMCS) conjugate
fluvoxamine
mucoadhesion
permeation
pharmacokinetics
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
31 Aug 2023
31 Aug 2023
Historique:
received:
14
07
2023
revised:
24
08
2023
accepted:
30
08
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Depression is the major mental illness which causes along with loss of interest in daily life, a feeling of hopelessness, appetite or weight changes, anger and irritability. Due to the hepatic first-pass metabolism, the absolute bioavailability of fluvoxamine (FVM) after oral administration is about 50%. By avoiding the pre-systemic metabolism, nasal delivery would boost bioavailability of FVM. Additionally, the absorption is anticipated to occur more quickly than it would via the oral route because of the existence of microvilli and high vasculature. A nonionic surfactant, cholesterol and an arachidonic acid-carboxymethyl chitosan (AA-CMCS) conjugate were used to develop FVM-loaded novasomes. To investigate the effects of surfactant concentration, AA-CMCS conjugate concentration and stirring speed on the novasomes' characteristics, a Box-Behnken design was used. The dependent variables chosen were zeta potential, polydispersity index and particle size. The AA-CMCS conjugate was confirmed by
Identifiants
pubmed: 37765228
pii: pharmaceutics15092259
doi: 10.3390/pharmaceutics15092259
pmc: PMC10535484
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Pharm. 2022 Sep 25;625:122068
pubmed: 35926753
Cells. 2022 Jul 05;11(13):
pubmed: 35805207
Biol Pharm Bull. 2022;45(4):538-541
pubmed: 35370281
Int J Biol Macromol. 2020 Dec 1;164:2691-2700
pubmed: 32810533
Int J Mol Sci. 2022 Mar 30;23(7):
pubmed: 35409171
Biomolecules. 2022 May 22;12(5):
pubmed: 35625657
Eur J Pharm Biopharm. 2017 May;114:22-28
pubmed: 28089914
Int J Nanomedicine. 2021 Jan 08;16:119-132
pubmed: 33447031
Biol Pharm Bull. 2001 Jul;24(7):848-51
pubmed: 11456130
Clin Pharmacokinet. 1995;29 Suppl 1:1-9
pubmed: 8846617
Int J Biol Macromol. 2022 Jan 15;195:424-432
pubmed: 34920058
Int J Biol Macromol. 2022 Apr 15;204:373-385
pubmed: 35149096
Drug Deliv. 2022 Dec;29(1):2058-2071
pubmed: 35801404
Drug Deliv. 2022 Dec;29(1):2428-2441
pubmed: 35880688
J Pharm Anal. 2022 Apr;12(2):287-292
pubmed: 35582396
Molecules. 2017 Oct 05;22(10):
pubmed: 28981459
Molecules. 2022 May 04;27(9):
pubmed: 35566287
Int J Pharm. 2013 Jan 30;441(1-2):323-33
pubmed: 23178598
Carbohydr Polym. 2022 Aug 15;290:119490
pubmed: 35550774
J Drug Assess. 2020 Mar 31;9(1):72-81
pubmed: 32341840
Drugs. 1986 Oct;32(4):313-34
pubmed: 3096686
Colloids Surf B Biointerfaces. 2017 May 1;153:229-236
pubmed: 28258031
ACS Omega. 2022 Jun 07;7(24):21000-21013
pubmed: 35755329
Eur J Pharm Sci. 2020 Oct 1;153:105466
pubmed: 32673792
J Am Acad Child Adolesc Psychiatry. 2004 Dec;43(12):1497-505
pubmed: 15564819
J Vis Exp. 2015 Mar 02;(97):
pubmed: 25867960
Pharmaceutics. 2022 Jun 24;14(7):
pubmed: 35890227
Drug Deliv. 2016 Nov;23(9):3374-3386
pubmed: 27128792
Int J Biol Macromol. 2016 Apr;85:615-24
pubmed: 26778157
J Neurotrauma. 2022 Sep;39(17-18):1240-1261
pubmed: 35502478
New Microbes New Infect. 2022 Jun 01;47:100986
pubmed: 35668841
Indian J Pharm Sci. 2011 Nov;73(6):608-14
pubmed: 23112393
Pharmaceutics. 2022 Apr 16;14(4):
pubmed: 35456709